secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2024-10-21T23:59:59+00:00
Accession:  0000950170-24-115800
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics completes enrollment in Phase 2a RIVER trial of Haduvio; topline data due Q1 2025
--------------------------------------------------------------------------------

- Trevi Therapeutics (Nasdaq: TRVI) completed enrollment in its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER).
- The trial is evaluating Haduvio for the treatment of refractory chronic cough.
- Topline data from the RIVER trial is expected to be reported in the first quarter of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024115800/0000950170-24-115800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024115800/trvi-20241021.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-115800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer